Literature DB >> 2949012

Expression in Escherichia coli of fully active recombinant human IL 1 beta: comparison with native human IL 1 beta.

M J Tocci, N I Hutchinson, P M Cameron, K E Kirk, D J Norman, J Chin, E A Rupp, G A Limjuco, V M Bonilla-Argudo, J A Schmidt.   

Abstract

Although complementary DNA (cDNA) encoding human interleukin 1 beta (IL 1 beta) have been cloned in several laboratories, there are as yet no data demonstrating that recombinant IL 1 beta (rIL 1 beta) molecules expressed from such cDNA are faithful, fully active replicas of the native protein secreted by human monocytes. To this purpose, cDNA sequences corresponding to the exact NH2-terminus and amino acid sequence of mature, monocyte-derived human IL 1 beta were placed under control of the inducible trp-lac (TAC) fusion promoter and were expressed in E. coli strain JM105. rIL 1 beta was purified to homogeneity by high pressure liquid chromatography (HPLC). Yields of 10 to 20 mg of rIL 1 beta/liter/10(11) cells were obtained. Purified rIL 1 beta was then compared in a number of biochemical and biologic assays to purified native IL 1 beta. Native and rIL 1 beta co-migrated on SDS-polyacrylamide gels as 17.5 kd polypeptides and reacted with specific polyclonal antisera raised to three synthetic peptides of human IL 1 beta in immunoblot experiments. Amino acid sequence analysis of rIL 1 beta showed that the native amino terminus, an ALA residue, was faithfully maintained. Purified native and rIL 1 beta co-chromatographed on reverse-phase HPLC. Specific biologic activities of rIL 1 beta were indistinguishable from those of the native protein in murine thymocyte and human dermal fibroblast proliferation assays, with half-maximal stimulation occurring at concentrations of 25 pM in the murine thymocyte assay and 2 pM in the human dermal fibroblast assay. Similarly, native and rIL 1 beta competed equally well for high affinity IL 1 receptor binding sites, each exhibiting a Ki of 20 pM on MRC-5 human embryonic lung fibroblasts. These observations indicate that E. coli efficiently expresses large quantities of rIL 1 beta, which emulates exactly the properties of the native protein.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2949012

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Lipopolysaccharide-induced cytokine production in peripheral blood mononuclear cells: intracellular localization of tumor necrosis factor alpha and interleukin 1 beta detected with a three-color immunofluorescence technique.

Authors:  E S de Bont; A E Niemarkt; R Y Tamminga; J L Kimpen; W A Kamps; L H de Leij
Journal:  Histochem Cell Biol       Date:  1996-12       Impact factor: 4.304

2.  The Penn State Protein Ladder system for inexpensive protein molecular weight markers.

Authors:  Ryan T Santilli; John E Williamson; Yoshitaka Shibata; Rosalie P Sowers; Andrew N Fleischman; Song Tan
Journal:  Sci Rep       Date:  2021-08-18       Impact factor: 4.996

3.  Modulation of fibronectin gene expression in human mononuclear phagocytes.

Authors:  K Yamauchi; Y Martinet; R G Crystal
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

4.  Interleukin-1beta expression in human gastric carcinoma with Epstein-Barr virus infection.

Authors:  Ja-Mun Chong; Kazuya Sakuma; Makoto Sudo; Toshio Osawa; Etsuko Ohara; Hiroshi Uozaki; Junji Shibahara; Kenji Kuroiwa; Shin-Ichi Tominaga; Yoshitaka Hippo; Hiroyuki Aburatani; Nobuaki Funata; Masashi Fukayama
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

5.  Effect of trovafloxacin on production of cytokines by human monocytes.

Authors:  A A Khan; T R Slifer; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

6.  Interleukin 1 beta is localized in the cytoplasmic ground substance but is largely absent from the Golgi apparatus and plasma membranes of stimulated human monocytes.

Authors:  I I Singer; S Scott; G L Hall; G Limjuco; J Chin; J A Schmidt
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.